Miocamycin。回顾其抗菌活性、药代动力学性质和治疗的潜力。

文章的细节

引用

复制到剪贴板

霍利迪SM, Faulds D

Miocamycin。回顾其抗菌活性、药代动力学性质和治疗的潜力。

药。1993年10月,46 (4):720 - 45。doi: 10.2165 / 00003495-199346040-00008。

PubMed ID

7506653 (在PubMed

]

文摘

Miocamycin是一个口头管理16国大环内酯物抗菌药物。它有一个范围的体外活性与红霉素相似,抑制各种革兰氏阳性和革兰氏阴性细菌,非典型微生物和一些厌氧菌。重要的是,miocamycin演示了体外药效比红霉素对一些病原体包括嗜肺性军团菌、支,Ureaplasma体。同样值得注意的是其活动对erythromycin-resistant葡萄球菌和链球菌物种表达inducible-type阻力。Miocamycin拥有糟糕的整体活动对流感嗜血杆菌和不活跃的肠杆菌科。miocamycin渗透到身体组织和体液是快速和广泛的。3 miocamycin具有抗菌活性的主要代谢产物,可能导致药物的治疗效果。临床数据表明miocamycin是有用的治疗上、下呼吸道感染的成人和儿科患者。Miocamycin也是有效的治疗尿道感染沙眼衣原体引起的或体。一些研究显示,miocamycin至少是一样有效的红霉素在这些迹象; however, comparisons with newer macrolide agents have yet to be performed. In other studies, miocamycin proved to be a useful agent in the treatment of periodontal infections and as anti-infective prophylaxis in dental surgery. Miocamycin appears to have a tolerability profile qualitatively similar to that of other macrolides, with gastrointestinal and skin disorders being the most commonly reported adverse events. Current data suggest that the potential for drug interactions with miocamycin is low, with the possible exceptions of carbamazepine and cyclosporin. Thus, although further confirmation and elaboration of various aspects of its efficacy and tolerability profile is needed, at this stage miocamycin offers a useful alternative oral therapy to erythromycin for the treatment of uncomplicated community-acquired respiratory tract infections and nongonococcal urethritis.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Miocamycin